Abstract:ID 96214 Poster Board 484 Statement of the Problem . Epilepsy is the 4 th common neurological disorder after Parkinson's and Alzheimer's Disease and Stroke, with 3 million people in the US and 65 million people worldwide living with epilepsy. At the molecular level, it is known that voltage-gated sodium (VGSC) and calcium channels are related to the onset of seizures. Our lab engages in early drug design and discovery of novel small molecules as potential anti-seizure analogs, for epilepsy. Previous hit-to-lead optimization and target identification studies performed by our research team, led to the discovery of lead compound, ETSP 518001.This analog has been shown to act as a potent and selective Ca v 3.2 and Ca v 3.3 T-type voltage-gated calcium channel (T-VGCC) inhibitor. The objective of the work presented is to evaluate the inhibitory effects of several novel enaminone derivatives based on the prototype ETSP 518001 to identify new lead compounds as T-VGCC inhibitors. Methods: To design the novel enaminone derivatives, we utilized MedChem Studio, a simulation program to determine the druggability of the desired small molecules. Preliminary in vitro whole cell patch clamp experiments were performed to assess the inhibitory effects of several target analogs on voltage-activated Ca 2+ currents in human embryonic kidney (HEK-293) cells. Cav3.2 transfected HEK 293 cells were treated with 50 μM of test compounds and compared to the control group (none pretreated HEK 293 cells). Statistical analyses consisted of t-test for pairwise comparisons or one-way ANOVA followed by post hoc analysis using Tukey's honest significant difference test for comparisons between multiple groups. To validate the biological activity, studies were conducted at the National Institutes of Neurological Disorders and Stroke Epilepsy Therapy Screening Program, NIH. ETSP 578001 was investigated in acute rodent seizure models, to determine the efficacy and safety as an anti-seizure agent. Results. Each enaminone analog in our novel series were examined in MedChem studio and were calculated to have an average CLogP value of 2.96, and predicted to have high blood brain barrier permeability (99%). Preliminary in vitro studies showed ETSP 578001 has ≥ 90% inhibition of T-VGCC current, generated by the Ca v 3.2 subunit. Enaminone analog RHB62 caused a reduction in the Ca 2+ current, with lower potency than ETSP 578001. No inhibitory effect was shown at a similar concentration for analogs RHB59, RHB95 or RHB103. Further research showed that ETSP 578001 analog also inhibited VGSCs and had no effect on cell viability. These results show that ETSP 578001 had dual inhibition properties. Results from the preclinical in vivo study demonstrated that compound ETSP 587001 had low efficacy in the 6Hz 44 mA and the maximal electroshock (MES) rodent seizure model, as 0/4 animals were protected at pretreatment times 0.5h and 2h. Conclusion: A target-based drug design strategy was employed, that led to the discovery of ETSP 578001, as a dual VGSC and T-VGCC blocker. This analog showed toxicity in the ETSP rodent seizure model. Future studies will involve lead optimization and target identification studies on ETSP 578001. PhRMA Foundation, Pre-Doctoral Fellowship in Drug Discovvery University of Maryland Eastern Shore Richard A. Bernstein Endowment

A Caenorhabditis elegans assay of seizure-like activity optimised for identifying antiepileptic drugs and their mechanisms of action

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

Functional analysis of epilepsy-associated GABAA receptor mutations using Caenorhabditis elegans

Automated Tight Seal Electrophysiology for Assessing the Potential Herg Liability of Pharmaceutical Compounds

A zebrafish-centric approach to antiepileptic drug development

On-Demand Seizures Facilitate Rapid Screening of Therapeutics for Epilepsy

When Non-Promising Findings Also Go From Aquarium to Bedside: The Importance of Rigorous Preclinical Analyses of ASM Candidates

An Integrated in Vitro Human Ipscs-Derived Neuron and in Vivo Animal Approach for Preclinical Screening of Anti-Seizure Compounds.

Machine learning enables high-throughput, low-replicate screening for novel anti-seizure targets and compounds using combined movement and calcium fluorescence in larval zebrafish

Novel test strategies for in vitro seizure liability assessment

A microfluidic device for whole-animal drug screening using electrophysiological measures in the nematode C. elegans

Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis

Development and pharmacologic characterization of the rat 6 Hz model of partial seizures

Efficient strategies based on behavioral and electrophysiological methods for epilepsy-related gene screening in the Drosophila model

A Zebrafish-Based Platform for High-Throughput Epilepsy Modeling and Drug Screening in F0

The Drug Design and Discovery of Novel Enaminone Derivatives as Potential Anti-seizure Agents

Functional brain imaging in larval zebrafish for characterising the effects of seizurogenic compounds acting via a range of pharmacological mechanisms

Neuroprotection in C. Elegans Parkinsons Disease Models: Discovering Therapeutic Insights via RNAi and Small Molecule High Throughput Screening

New anti-epileptic drugs

High-throughput behavioral screen in C. elegans reveals Parkinson's disease drug candidates

Zebrafish as a Model for Epilepsy-Induced Cognitive Dysfunction: A Pharmacological, Biochemical and Behavioral Approach